Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31065690 | 0.88 | ALDH1A1 (0.64) | ALDH1A1MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2882110 | 0.88 | MAPK1 (0.67) | ALDH1A1MAPTCYP1A2CYP2C9MAPK1 | |
| SCHEMBL29283867 | 0.87 | ALDH1A1 (0.57) | ALDH1A1MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29283864 | 0.87 | ALDH1A1 (0.57) | ALDH1A1MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL31065676 | 0.86 | ALDH1A1 (0.67) | ALDH1A1MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2885173 | 0.85 | MEN1 (0.53) | ALDH1A1MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2885170 | 0.85 | MEN1 (0.53) | ALDH1A1MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL31065683 | 0.84 | NPSR1 (0.68) | ALDH1A1MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL31065681 | 0.81 | ALDH1A1 (0.57) | ALDH1A1MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL31065689 | 0.81 | ALDH1A1 (0.66) | ALDH1A1MAPTCYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | disclosed |
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | LABORATOIRES SERONO S.A. (CH) | 2009-12-10 | — | — | US | disclosed |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2006-06-08 | — | — | US | disclosed |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | ZAP70, BRCA1, ZYX | ALDH1A1 716/4885MAPT 3408/4885CYP1A2 651/4885 |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | CATSPER1, PI4KB, MAN2B2 | ALDH1A1 1935/4885MAPT 4185/4885CYP1A2 3293/4885 |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | BRCA1, ZAP70, F13B | ALDH1A1 678/4885MAPT 3523/4885CYP1A2 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.